Acute Myeloid Leukemia (AML). Acute myeloblastic leukemia
Conditions
Interventions
Intervention group: Patients with acute resistant myeloid leukemia who receive conditioning regimen 3 days before cell therapy then 5-10 million cell per kilogram of patient weight would be infused in
Sponsors
Motamed Cancer Institute
Modiriat Atiye Bahman Company
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1- Age 18 to 70 years 2. Drug-resistant AML patients with no response to 2 treatments line or recurrent cases that can not be candidates for standard therapies or bone marrow transplants 3- The toxicity of chemotherapy regimens ( such as severe cytopenia) should be assigned and it would be checked as a regimen with no significant side effects. 4- PS=2[Performance Status (PS)] 5- The results of these tests should be available:• [glomerular filtration rate (GFR)] GFR=60 or CR=2 mg / dl• ALT 92% in room air• Cardiac classification status (III> NHC) or [ejection fraction]EF> 50%• Negative pregnancy test• Negative HIV testing
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Possible symptoms of hyper-sensitivity and allergy after injection. Timepoint: Daily until the third day after the injection and then weekly until the day +90 after the injection. Method of measurement: Using CTCAE check list.;Decrease of tumor burden. Timepoint: A week after injection and every month until 3 months. Method of measurement: Physical Examination, Flow cytometry, CBC.;Graft versus host disease (GVHD) symptoms. Timepoint: Daily until the third day after the injection and then weekly until the day +90 after the injection. Method of measurement: Physical examination - Imaging - Laboratory tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ramin Sarrami Forooshani
Iranian academic center for education culture and research
Outcome results
None listed